PDC-CRO Report issue

For profit Phase 2 Phase 3
Founded: Dubai United Arab Emirates (2011)

Organization Overview

First Clinical Trial
2020
NCT04656613
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

PDC-CRO

Active Ingredients

Drugs in Phase 3 Trials (1)

gam-covid-vac lyo (1 trial)

Drugs in Phase 2 Trials (1)

bone marrow derived mesenchymal stem cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 3)

Infections (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2